A Study of Olomorasib (LY3537982) in Healthy Participants

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT07439250
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Olomorasib — DRUG
    Administered orally
  • Fluconazole — DRUG
    Administered orally

Study Details

The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overnight stays in the research center.

Key Dates

Start date
Mar 2, 2026
Status verified
May 2026
Primary completion
Apr 17, 2026
Completion
Apr 17, 2026

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Other: Olomorasib + Fluconazole
    Administered orally
  • Other: Olomorasib
    Administered orally

Primary Outcome Measure

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Olomorasib [ Time Frame: Baseline, Day 12 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit - Daytona BeachDaytona BeachFlorida32117-5116-

Find similar trials in Daytona Beach, FL

By research site
Fortrea Clinical Research Unit - Daytona Beach· Daytona Beach, FL

Related Studies